

Short Report: Comparison of Performance of Serum and Plasma in Panbio Dengue and Japanese Encephalitis Virus Enzyme-Linked Immunosorbent Assays

Stuart D. Blacksell,* Sue J. Lee, Anisone Chanthongthip, Thaksinaporn Taojaikong,† Soulignasack Thongpaseth, Tanja Hübscher, and Paul N. Newton

Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos; Mahidol University-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom; Travel and Tropical Medicine and General Medicine, Hohmad Clinic, Thun, Switzerland

Abstract. We examined the comparative performance of serum and plasma (in dipotassium EDTA) in Panbio Dengue enzyme-linked immunosorbent assays (ELISAs) for detection of non-structural protein 1 (NS1), IgM, and IgG, and a dengue/Japanese encephalitis virus (JEV) combination IgM ELISA in a prospective series of 201 patients with suspected dengue in Laos. Paired comparisons of medians from serum and plasma samples were not significantly different for Dengue IgM, and NS1 which had the highest number of discordant pairs (both 2%; $P = 0.13$ and $P = 0.25$, respectively). Comparison of qualitative final diagnostic interpretations for serum and plasma samples were not significantly different: only 1.5% (3 of 201 for Dengue/JEV IgM and Dengue IgG) and 2.0% (4 of 201; IgM and NS1) showed discordant pairs. These results demonstrate that plasma containing EDTA is suitable for use in these ELISAs.

Manufacturers of diagnostic assays make specific recommendations for the sample matrix to be used for testing because blood preservatives or anticoagulants may affect assay performance. Serum centrifuged from clotted blood is often the sample of choice because it contains no chemical additives. Instructions for many commercial enzyme-linked immunosorbent assays (ELISAs) and rapid tests for diagnosis of acute dengue and Japanese encephalitis virus (JEV) infections do not state whether plasma may be used and, if so, which anticoagulant agents, such as lithium heparin, sodium fluoride, potassium oxalate, or EDTA, are appropriate.

We have therefore examined the comparative performance of paired serum and plasma samples of four well-established and previously assessed Panbio ELISAs (Alere, Brisbane, Queensland, Australia) for detection of dengue virus non-structural protein 1 (NS1),¹ IgM,² IgG,² and a JEV IgM³ ELISA. These kits state that the test should be performed on serum only and that the use of whole blood, plasma, or other specimen matrix has not been established.

Samples ($n = 201$) were prospectively collected from all patients with suspected dengue-like or JEV-like illness at Mahosot Hospital, Vientiane, Laos during August–November 2010. Ethical clearance was provided by the Ethical Review Committee of the Faculty of Medical Sciences, National University of Laos (Vientiane, Laos) and the Oxford University Tropical Ethics Research Committee (Oxford, United Kingdom).

After informed written consent was obtained, patients were admitted to the study if the responsible physician diagnosed suspected dengue, defined as an acute febrile illness with ≥ 2 of the following features: headache, retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestations, or leukopenia according to World Health Organization guidelines.⁴ Venous blood samples were collected on the

day of admission (admission specimen) and on the day of discharge from hospital (convalescent specimen). Serum was prepared by centrifugation of 5 mL of whole blood that was collected into plain 5-mL polystyrene blood collection tubes sterilized with gamma irradiation (Z6744; Teklab, Sacriston, United Kingdom), allowed to clot, and then centrifuged at $2,000 \times g$ for 10 minutes. Plasma was prepared by centrifugation, as for serum, from 5 mL whole blood collected into 5-mL blood collection tubes containing 1.75 mg of dipotassium EDTA/mL (catalog no. K6740; Teklab). The two sample types were taken from the same blood draw with the same syringe and stored in the same -80°C freezers until ELISAs were performed.

The assays assessed were the Panbio Dengue Early NS1 antigen (catalog no. E-DEN01P second generation; Alere), Panbio Dengue IgM capture (catalog no. E-DEN01M; Alere), Dengue IgG capture (catalog no. DEN02G; Alere), and Panbio Japanese Encephalitis/Dengue IgM combo (catalog no. E-JED01C; Alere) ELISAs. Serum and plasma samples were tested in duplicate on the same ELISA plate to minimize variation. All assays were performed according to the manufacturer's instructions and results (Panbio Units) and final interpretations were calculated (i.e., dengue or JEV positive, negative, or inconclusive) as per the prescribed method. Inconclusive results were considered negative.

Quantitative (Panbio units) and qualitative results (positive or negative) for paired serum and plasma samples for each ELISA were compared by using STATA version 10.0 (StataCorp LP, College Station, TX). The Wilcoxon signed-rank test for matched pairs was used to test equality of Panbio Units for each ELISA. Differences in qualitative results for final assay interpretation were assessed by using McNemar's chi-square test. The range within which one would expect 95% of the values from the paired samples to lie (i.e., limits of agreement) were calculated by using the Bland-Altman method for each ELISA.^{5,6} P values < 0.05 were considered significant.

Comparison of the Panbio unit values and of final interpretations (positive or negative using manufacturer's criteria) for all ELISAs (Table 1) demonstrated no significant differences, with the exception of the JEV/Dengue Combo

*Address correspondence to Stuart D. Blacksell, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand. E-mail: stuart@tropmedres.ac
†Deceased.

TABLE 1
Quantitative (Panbio units) results for comparison of 201 paired serum and plasma samples tested in Panbio dengue/JEV ELISAs*

ELISA	Target	Sample	Overall		Difference		Final interpretation†	
			Median Panbio units (IQR)	Wilcoxon signed-rank value (<i>P</i>)	Mean (95% CI)	Bland and Altman 95% limits of agreement	Discordant pairs, no. (%)	McNemar's χ^2 (<i>P</i>)
Dengue/JEV IgM	Dengue IgM	Serum	36.47 (8.82–50.84)	2.34 (0.02)	1.0 (–0.18 to 2.18)	–15.67 to 17.67	3 (1.5)	2.0 (0.5)
		Plasma	31.46 (8.19–49.4)					
	JEV IgM	Serum	8.70 (5.38–17.31)	–1.62 (0.11)	0.07 (–0.73 to 0.89)	–11.51 to 11.65	0	0
		Plasma	8.90 (5.08–16.32)					
IgG capture	Dengue IgG	Serum	14.51 (2.56–45.15)	0.76 (0.45)	0.12 (–0.56 to 0.80)	–9.50 to 9.74	3 (1.5)	0.0 (1.0)
		Plasma	14.78 (2.69–44.6)					
IgM capture	Dengue IgM	Serum	27.81 (7.49–44.87)	0.61 (0.54)	0.39 (–0.48 to 1.25)	–11.82 to 12.59	4 (2.0)	4.0 (0.13)
		Plasma	26.72 (6.44–46.72)					
NS1	Dengue NS1	Serum	43.71 (2.06–54.27)	0.33 (0.74)	0.61 (–0.51 to –1.72)	–15.12 to 16.33	4 (2.0)	3.0 (0.25)
		Plasma	41.57 (1.97–54.52)					

*JEV = Japanese encephalitis virus; ELISA = enzyme-linked immunosorbent assay; IQR = interquartile range; CI = confidence interval; NS1 = non-structural protein 1.

†Using Panbio criteria.

IgM ELISA, which showed significantly different results for plasma and serum for the Panbio unit comparison ($P = 0.02$) but not for the final interpretation ($P = 0.5$). There were 1.5% (3 of 201) discordant pairs for the IgG capture

ELISA and 2.0% (4 of 201) discordant pairs for the IgM capture and NS1 antigen ELISAs (Table 1). Mean differences for serum and plasma Panbio units was generally small ranging from 0.07 (JEV Combo IgM capture ELISA) to 1.0 (JEV/Dengue Combo IgM capture ELISA) (Table 1). Bland and Altman 95% limits of agreement ranged from –9.50 to 9.74 for the IgG capture ELISA to –15.67 to 17.67 for the JEV/Dengue Combo IgM capture ELISA (Table 1 and Figure 1). Comparison of Panbio unit results for dengue-positive and dengue-negative samples as determined by using the assay interpretation criteria (Table 2 and Figure 2), demonstrated that with the exception of the JEV/Dengue Combo IgM capture ELISA ($P = 0.03$), there were no significant differences.

These results suggest that plasma is a suitable sample for use in Panbio dengue and JEV ELISAs. Other studies with immunoassays for C-reactive protein,⁷ N-terminal pro-brain natriuretic peptide,⁸ and cryptococcal antigen⁹ have also demonstrated that results from serum and plasma samples are comparable. Other factors that can potentially affect ELISA results are temperature storage conditions and repeated freeze–thaw cycles. However, these affects appear to be less pronounced for ELISA detection of antibodies and viral antigens.^{10–12} Further studies are required to determine the affect of other anticoagulant agents such as lithium heparin, sodium fluoride and potassium oxalate, as well as the affect of sample timing, on anticoagulant-treated samples on assay performance.




FIGURE 1. Difference against mean plot for plasma and serum Panbio units for (A) nonstructural protein 1 (NS1), (B) IgM, and (C) IgG enzyme-linked immunosorbent assays (ELISAs). Bland and Altman 95% limits of agreement (dashed lines) and mean (solid lines) are indicated.

TABLE 2

Comparison of Panbio units results for 201 dengue-positive and dengue-negative serum and plasma samples tested in Panbio dengue/JEV ELISAs*

ELISA	Infection	Dengue status†	No.	Wilcoxon signed-rank <i>P</i>
Dengue/JEV IgM	Dengue	Positive	148	0.03
		Negative	53	0.38
	JEV	Positive	148	0.14
		Negative	53	0.42
IgG capture	Positive	83	0.79	
	Negative	118	0.20	
IgM capture	Positive	142	0.91	
	Negative	59	0.38	
NS1	Positive	128	0.73	
	Negative	73	0.95	

*JEV = Japanese encephalitis virus; ELISA = enzyme-linked immunosorbent assay; range; NS1 = non-structural protein 1.

†Using Panbio criteria for serum samples.




FIGURE 2. Difference against mean plot for plasma and serum Panbio units for combination (A) dengue and (B) Japanese encephalitis virus (JEV) IgM enzyme-linked immunosorbent assays (ELISAs). Bland and Altman 95% limits of agreement (dashed lines) and mean (solid lines) are indicated.

Received January 19, 2012. Accepted for publication May 21, 2012.

Acknowledgments: We thank the directors, doctors, and nurses of Mahosot Hospital; the Director (Dr. Rattanaphone Phetsouvanh), and staff of the Microbiology Laboratory, Mahosot Hospital; and the Minister of Health and the Director of the Curative Department, Ministry of Health, for assistance and support during this study, which was part of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit.

Financial support: The study was supported by the Wellcome Trust of the United Kingdom. Alere supplied the kits used in this study.

Disclosure: None of the authors have any conflicts of interest, and Alere had no role in the analysis, writing, or decision to publish these data.

Authors' addresses: Stuart D. Blacksell, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Rajthevee, Bangkok 10400, Thailand, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, United Kingdom; and Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos, E-mail: stuart@

tropmedres.ac. Sue J. Lee, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Rajthevee, Bangkok 10400, Thailand; and Centre for Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, United Kingdom, E-mail: sue@tropmedres.ac. Anisone Chanthongthip and Soulignasack Thongpaseuth, Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos, E-mails: anisone@tropmedres.ac and sak@tropmedres.ac. Tanja Hübscher, Travel and Tropical Medicine and General Medicine, Hohmad Clinic, Thun, Switzerland, E-mail: huebscher@yahoo.com. Paul N. Newton, Centre for Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, United Kingdom; and Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos, E-mail: paul@tropmedres.ac.

REFERENCES

1. Blacksell SD, Mammen MP Jr, Thongpaseuth S, Gibbons RV, Jarman RG, Jenjaroen K, Nisalak A, Phetsouvanh R, Newton PN, Day NP, 2008. Evaluation of the Panbio dengue virus nonstructural 1 antigen detection and immunoglobulin M antibody enzyme-linked immunosorbent assays for the diagnosis of acute dengue infections in Laos. *Diagn Microbiol Infect Dis* 60: 43–49.
2. Vaughn DW, Nisalak A, Solomon T, Kalayanarooj S, Nguyen MD, Kneen R, Cuzzubbo A, Devine PL, 1999. Rapid serologic diagnosis of dengue virus infection using a commercial capture ELISA that distinguishes primary and secondary infections. *Am J Trop Med Hyg* 60: 693–698.
3. Ravi V, Robinson JS, Russell BJ, Desai A, Ramamurthy N, Featherstone D, Johnson BW, 2009. Evaluation of IgM antibody capture enzyme-linked immunosorbent assay kits for detection of IgM against Japanese encephalitis virus in cerebrospinal fluid samples. *Am J Trop Med Hyg* 81: 1144–1150.
4. World Health Organization, 2009. *Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control*. Geneva: World Health Organization.
5. Bland JM, Altman DG, 1986. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1: 307–310.
6. Bland JM, Altman DG, 2003. Applying the right statistics: analyses of measurement studies. *Ultrasound Obstet Gynecol* 22: 85–93.
7. Brindle E, Fujita M, Shofer J, O'Connor KA, 2010. Serum, plasma, and dried blood spot high-sensitivity C-reactive protein enzyme immunoassay for population research. *J Immunol Methods* 362: 112–120.
8. Chien TI, Chen HH, Kao JT, 2006. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. *Clin Chim Acta* 369: 95–99.
9. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, Longley N, Harrison TS, Kozel TR, 2011. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. *Clin Infect Dis* 53: 1019–1023.
10. Fipps DR, Damato JJ, Brandt B, Burke DS, 1988. Effects of multiple freeze thaws and various temperatures on the reactivity of human immunodeficiency virus antibody using three detection assays. *J Virol Methods* 20: 127–132.
11. Hendry RM, McIntosh K, 1982. Enzyme-linked immunosorbent assay for detection of respiratory syncytial virus infection: development and description. *J Clin Microbiol* 16: 324–328.
12. Pinsky NA, Huddlestone JM, Jacobson RM, Wollan PC, Poland GA, 2003. Effect of multiple freeze-thaw cycles on detection of measles, mumps, and rubella virus antibodies. *Clin Diagn Lab Immunol* 10: 19–21.